Article
Medicine, General & Internal
Jacques Donnez, Hugh S. Taylor, Elizabeth A. Stewart, Linda Bradley, Erica Marsh, David Archer, Ayman Al-Hendy, Felice Petraglia, Nelson Watts, Jean-Pierre Gotteland, Elke Bestel, Paul Terrill, Ernest Loumaye, Andrew Humberstone, Elizabeth Garner
Summary: The results of two phase 3 trials demonstrated that Linzagolix significantly reduced heavy menstrual bleeding and the partial suppression of Linzagolix (100 mg) as a monotherapy provides a unique treatment option for women with symptomatic uterine fibroids who are unable or unwilling to take hormonal add-back therapy.
Article
Medicine, General & Internal
Alexa B. Kimball, Gregor B. E. Jemec, Afsaneh Alavi, Ziad Reguiai, Alice B. Gottlieb, Falk G. Bechara, Carle Paul, Evangelos J. Giamarellos Bourboulis, Axel P. Villani, Andreas Schwinn, Franziska Rueff, Larisha Pillay Ramaya, Adam Reich, Ines Lobo, Rodney Sinclair, Thierry Passeron, Antonio Martorell, Pedro Mendes-Bastos, Georgios Kokolakis, Pierre-Andre Becherel, Magdalena B. Wozniak, Angela Llobet Martinez, Xiaoling Wei, Lorenz Uhlmann, Anna Passera, Deborah Keefe, Ruvie Martin, Clarice Field, Li Chen, Marc Vandemeulebroecke, Shoba Ravichandran, Elisa Muscianisi
Summary: Two randomized trials showed that secukinumab was clinically effective at rapidly improving signs and symptoms of moderate-to-severe hidradenitis suppurativa with a favorable safety profile and sustained response up to 52 weeks of treatment.
Article
Endocrinology & Metabolism
Jianping Xu, Hongwei Ling, Jianlin Geng, Yanli Huang, Ying Xie, Huiping Zheng, Huikun Niu, Tianhao Zhang, Jing Yuan, Xinhua Xiao
Summary: This study evaluated the efficacy and safety of DBPR108 as an add-on therapy in patients with inadequately controlled type 2 diabetes using metformin. The results showed that DBPR108 significantly improved glycemic control, with a higher proportion of patients achieving target HbA1c levels. DBPR108 also reduced fasting and postprandial glucose levels without causing weight gain. Overall, DBPR108 was effective and well-tolerated as an add-on therapy to metformin.
DIABETES OBESITY & METABOLISM
(2022)
Article
Food Science & Technology
Georgia Xiromerisiou, Ioannis C. Lampropoulos, Emmanouil V. Dermitzakis, Michail Vikelis, Chrysoula Marogianni, Dimitrios Mysiris, Andreas A. Argyriou
Summary: The study found that adding onabotulinumtoxinA (BoNTA) to carbamazepine or oxcarbazepine can be an effective treatment option for patients with treatment-refractory trigeminal neuralgia (TGN). A retrospective study on 15 patients showed that a single session of subcutaneous BoNTA injection significantly reduced TGN-related neuropathic pain, improved patients' quality of life, and provided a minimally invasive and well-tolerated treatment option.
Article
Gastroenterology & Hepatology
Siew C. Ng, Zhilu Xu, Joyce Wing Yan Mak, Keli Yang, Qin Liu, Tao Zuo, Whitney Tang, Louis Lau, Rashid N. Lui, Sunny H. Wong, Yee Kit Tse, Amy Y. L. Li, Kitty Cheung, Jessica Y. L. Ching, Vincent W. S. Wong, Alice P. S. Kong, Ronald C. W. Ma, Elaine Y. K. Chow, Simon K. H. Wong, Ivan Chak Hang Ho, Paul K. S. Chan, Francis K. L. Chan
Summary: Repeated FMTs enhance microbiota engraftment in obese patients with T2DM, leading to more favorable changes in recipients' microbiota and improvement in lipid profile and liver stiffness when combined with lifestyle intervention.
Article
Rheumatology
Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L. Thomas Klausch, Sabrina Paolino, Annemarie M. Schilder, Willem F. Lems, Maurizio Cutolo
Summary: This study compared the effects and side effects of low-dose prednisolone and placebo treatment in elderly patients with active rheumatoid arthritis. The results showed that low-dose prednisolone can reduce disease activity and joint damage, but the side effects also increased by 24%.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Psychiatry
Miyuru Chandradasa, Sameera Ruwanpriya, Silumini de Silva, Layani Rathnayake, K. A. L. A. Kuruppuarachchi
Summary: The lack of mental health professionals and individualised case management in resource-limited South Asian settings results in insufficient monitoring and personalised support for diet and physical exercise programmes in patients with schizophrenia. Topiramate has shown to be beneficial for weight reduction and symptomatic improvement in schizophrenia patients in South Asia.
ASIAN JOURNAL OF PSYCHIATRY
(2022)
Article
Multidisciplinary Sciences
Daniel Bradshaw, Iga Abramowicz, Stephen Bremner, Sumita Verma, Yvonne Gilleece, Sarah Kirk, Mark Nelson, Rosalie Housman, Helena Miras, Chloe Orkin, Ashini Fox, Michael Curnock, Louise Jennings, Mark Gompels, Emily Clarke, Rachel Robinson, Pauline Lambert, David Chadwick, Nicky Perry
Summary: Maraviroc may reduce hepatic inflammation in people with HIV-NAFLD through CCR5-receptor antagonism. The study showed that Maraviroc combined with optimized background therapy is safe and well-tolerated, with good recruitment, retention, and adherence rates.
Article
Rheumatology
Andrew Ostor, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Gabriela Alperovich, Wenjing Lu, Zailong Wang, Ahmed M. Soliman, Ann Eldred, Lisa Barcomb, Alan Kivitz
Summary: The study found that treatment with risankizumab resulted in significant improvements in key disease outcomes for patients with PsA who were Bio-IR and/or csDMARD-IR, and was well tolerated.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Lars Erik Kristensen, Mauro Keiserman, Kim Papp, Leslie McCasland, Douglas White, Wenjing Lu, Zailong Wang, Ahmed M. Soliman, Ann Eldred, Lisa Barcomb, Frank Behrens
Summary: Risankizumab treatment significantly improves signs and symptoms of PsA compared to placebo, demonstrating significant differences in skin and nail psoriasis endpoints, minimal disease activity, and resolution of enthesitis and dactylitis. Adverse events were reported at similar rates in the risankizumab and placebo groups.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Dermatology
E. Fontas, H. Montaudie, T. Passeron
Summary: The study demonstrated that gliadin-protected SOD could be a beneficial addition to phototherapy in the treatment of vitiligo patients, showing a greater improvement in repigmentation compared to the placebo group at 24 weeks, with good tolerance in both groups and no reported side effects.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Nutrition & Dietetics
Laura Aponte Becerra, Anna Gavrieli, Faizan Khan, Peter Novak, Vasileios Lioutas, Long H. Ngo, Vera Novak, Christos S. Mantzoros
Summary: Centrally administered insulin reduces appetite in animal studies but results are conflicting in humans. This study aimed to investigate the effect of intranasal insulin (INI) on food intake and other measures. The study found that INI had no effect on food intake, appetite, or body weight in older adults with and without type 2 diabetes.
CLINICAL NUTRITION
(2023)
Article
Rheumatology
Dinesh Khanna, Christopher P. Denton, Daniel E. Furst, Maureen D. Mayes, Marco Matucci-Cerinic, Vanessa Smith, Dick de Vries, Paul Ford, Yasmina Bauer, Matthew J. Randall, Mitra Ebrahimpoor, Laszlo Kupcsik, Pieter-Jan Stiers, Liesbeth Deberdt, Niyati Prasad, Sharlene Lim, Philippe Pujuguet, Sohail Ahmed
Summary: The study aimed to investigate the efficacy, safety, and tolerability of ziritaxestat in patients with early dcSSc. The results showed that ziritaxestat significantly reduced the modified Rodnan skin score compared to placebo and was well tolerated. Biomarker analysis suggested that ziritaxestat may reduce fibrosis. In conclusion, this study highlights the importance of ziritaxestat in improving skin involvement in patients with dcSSc.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Clinical Neurology
Eugenio Mercuri, Giovanni Baranello, Odile Boespflug-Tanguy, Liesbeth De Waele, Nathalie Goemans, Janbernd Kirschner, Riccardo Masson, Elena S. Mazzone, Astrid Pechmann, Maria Carmela Pera, Carole Vuillerot, Silvia Bader-Weder, Marianne Gerber, Ksenija Gorni, Janine Hoffart, Heidemarie Kletzl, Carmen Martin, Tammy McIver, Renata S. Scalco, Wai Yin Yeung, Laurent Servais
Summary: The study demonstrated a twofold increase in SMN protein after treatment with risdiplam, suggesting its potential effectiveness in treating spinal muscular atrophy. Additionally, the safety profile of risdiplam supported the continuation of the pivotal Part 2 study.
EUROPEAN JOURNAL OF NEUROLOGY
(2023)
Article
Endocrinology & Metabolism
Yuan-Di Halvorsen, Annie L. Conery, John Paul Lock, Wenjiong Zhou, Mason W. Freeman
Summary: This study aimed to evaluate the safety and effectiveness of bexagliflozin as an adjunct treatment for type 2 diabetes mellitus. The results showed significant improvements in glycemic control, blood pressure, and weight in the bexagliflozin group compared to the placebo group, with fewer adverse events.
DIABETES OBESITY & METABOLISM
(2023)
Review
Medicine, Research & Experimental
Marc Evans, Ruth D. Lewis, Angharad R. Morgan, Martin B. Whyte, Wasim Hanif, Stephen C. Bain, Sarah Davies, Umesh Dashora, Zaheer Yousef, Dipesh C. Patel, W. David Strain
Summary: The passage discusses the progression and complications of chronic kidney disease, as well as the challenges in treatment and the expected rise in prevalence due to increasing elderly population and comorbidities associated with the disease.
ADVANCES IN THERAPY
(2022)
Article
Pharmacology & Pharmacy
Marc Evans, Angharad R. Morgan, Martin B. Whyte, Wasim Hanif, Stephen C. Bain, Philip A. Kalra, Sarah Davies, Umesh Dashora, Zaheer Yousef, Dipesh C. Patel, W. David Strain
Summary: Chronic kidney disease is a serious and progressive condition with significant patient morbidity, where SGLT2 inhibitors have been firmly established as an effective strategy to slow down its progression and reduce associated complications. With updated licensing and guidelines for SGLT2 inhibitors, there is a need to include this class of drugs in standard care for CKD management.
Article
Peripheral Vascular Disease
Kunihiko Aizawa, Phillip E. Gates, David M. Mawson, Salim Elyas, Francesco Casanova, Kim M. Gooding, Damilola D. Adingupu, W. David Strain, Angela C. Shore
Summary: This study found that different methods of measuring carotid-femoral pulse wave velocity (CFPWV) can affect the results and the association with cardiovascular risk factors, but not the association with subclinical biomarkers of vascular health.
JOURNAL OF HYPERTENSION
(2022)
Article
Urology & Nephrology
Jennifer Williams, Mark Gilchrist, William David Strain, Donald Fraser, Angela Shore
Summary: The study found no significant correlation between systemic microcirculatory function and rate of SST or albumin clearance. However, dialysate interleukin-6 concentrations were significantly correlated with both SST and albumin clearance. This suggests that intraperitoneal factors, particularly inflammation, have a greater impact on SST rate than systemic factors.
PERITONEAL DIALYSIS INTERNATIONAL
(2022)
Article
Urology & Nephrology
Jennifer Williams, Mark Gilchrist, William David Strain, Donald Fraser, Angela Shore
Summary: This study compared 24-hour glycemic profiles of PD patients without diabetes with CKD-5 controls using continuous glucose monitoring (CGM). The results showed systematically different glycemic patterns in APD and CAPD patients, including higher nocturnal glucose in APD and absence of physiological nocturnal glucose dipping in APD. Comprehensive CGM data highlighted subtleties not appreciated by traditional metabolic biomarkers, suggesting implications for future research on the metabolic impact of PD.
PERITONEAL DIALYSIS INTERNATIONAL
(2022)
Review
Cardiac & Cardiovascular Systems
Jingzhou He, Nick G. Bellenger, Andrew J. Ludman, Angela C. Shore, W. David Strain
Summary: Acute myocardial infarction is a major global health issue, and timely reperfusion with primary percutaneous coronary intervention is commonly used. However, some patients develop post-infarct heart failure. Therapeutic interventions for ischemia-reperfusion injury have shown progress, but face difficulties in translation to clinical practice.
REVIEWS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Endocrinology & Metabolism
Rebecca Heath, Hakon Johnsen, W. David Strain, Marc Evans
Summary: Heart failure with preserved ejection fraction (HFpEF) is a growing condition with limited treatment options. However, promising results from recent studies indicate that SGLT2 inhibitors may have a significant impact on reducing cardiovascular death or hospitalization for heart failure in HFpEF patients.
Article
Endocrinology & Metabolism
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Debbie Hicks, Pam Brown, Zaheer Yousef, Umesh Dashora, Adie Viljoen, Hannah Beba, W. David Strain
Summary: Oral semaglutide, as a new option for treating T2D, has the potential to address therapy inertia and improve patient adherence, especially during the COVID-19 pandemic.
Article
Immunology
Tinevimbo Shiri, Marc Evans, Carla A. Talarico, Angharad R. Morgan, Maaz Mussad, Philip O. Buck, Phil McEwan, William David Strain
Summary: The vaccination program is reducing the burden of COVID-19, but recent increases in infections in Europe indicate vaccine efficacy is waning. Booster doses are needed to restore immunity levels. The rate of vaccine efficacy waning has a significant impact on COVID-19 hospitalizations, particularly in populations with lower vaccination coverage. The benefit of a booster vaccination strategy outweighs targeting the unvaccinated population once a majority of the population has received their primary vaccination course.
Article
Clinical Neurology
W. David Strain, Ofir Frenkel, Martin A. James, Lawrence A. Leiter, Soren Rasmussen, Peter M. Rothwell, Maria Sejersten Ripa, Thomas C. Truelsen, Mansoor Husain
Summary: This post hoc analysis found that GLP-1 RA drug semaglutide can reduce stroke risk in patients with type 2 diabetes, especially the risk of small-vessel occlusion, compared to placebo.
Review
Endocrinology & Metabolism
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Umesh Dashora, Smeeta Sinha, Samuel Seidu, Dipesh C. Patel, Hannah Beba, W. David Strain
Summary: The disease burden in people with diabetes is mainly caused by long-term complications. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown beneficial effects in reducing morbidity and mortality across the cardiorenal metabolic continuum, regardless of the presence of diabetes. However, the complexity of label indications and misconceptions about side effects have led to a lack of understanding in primary care regarding the use of SGLT2is.
Article
Immunology
William David Strain, Ondine Sherwood, Amitava Banerjee, Vicky Van der Togt, Lyth Hishmeh, Jeremy Rossman
Summary: This survey suggests that COVID-19 vaccination may improve symptoms in patients with long COVID, although individual responses vary. Validation through randomized controlled trials is needed.
Review
Geriatrics & Gerontology
Marc Evans, Angharad R. Morgan, Sarah Davies, Hannah Beba, William David Strain
Summary: SGLT2 inhibitors are considered an effective therapeutic option for older frail adults, as they help reduce the risk of cardiovascular events and renal diseases. Despite favorable clinical trial data, there is still some hesitation in their practical application.
Review
Radiology, Nuclear Medicine & Medical Imaging
F. Alghamdi, R. Owen, R. E. M. Ashton, A. D. Obotiba, R. M. Meertens, E. Hyde, M. A. Faghy, K. M. Knapp, P. Rogers, W. D. Strain
Summary: The COVID-19 pandemic has resulted in a global health crisis, with millions of deaths and long-term health changes in survivors. This review explores long COVID symptoms, diagnosis, and its potential impact on imaging services. Long COVID affects a significant proportion of vaccinated and unvaccinated individuals, with ongoing symptoms lasting for 12 or more weeks. The demand for imaging, especially CT scans for lung disease assessment, is expected to increase.
Article
Virology
Christina M. M. van der Feltz-cornelis, Andrew S. S. Moriarty, William David Strain
Summary: There is a belief that Long COVID could have a purely functional origin. Labelling patients with neurological dysfunction in Long COVID as having functional neurological disorder (FND) without proper testing is problematic. This practice prevents Long COVID patients with motor and balance symptoms from receiving appropriate care, while treatment for FND is often ineffective. Research is needed to determine whether motor and balance symptoms diagnosed as FND should be considered part of Long COVID or if they truly represent FND.